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INTRODUCTION
Severe combined immune deficiency syndrome (SCID)
is an inherited immune disorder characterized by lack of
cellular and humoral immunity leading to severe and
recurrent infections. Clinical features include recurrent
or persistent severe infections starting from the first few
months of life, which results in progressive failure to
thrive and death during infancy if left untreated.1 Early
stem cell transplant therapy within the first 3 months of
life has upto 95% chance of success, however, the
success rate progressively decreases with the increase
age.2,3
The global incidence of SCID is estimated to be 1 per
40,000 – 75,000 newborns.4 There are no published
data regarding the incidence of SCID in Pakistan. SCID
is more common in countries where consanguineous
marriage rates are high;1,5 and Pakistan has one of the
highest reported consanguineous rate in the world with
approximately two thirds of all marriages being
consanguineous.6
An excellent screening test for SCID is the absolute
lymphocyte count (ALC), which can be easily calculated
with the help of routine complete blood count with
manual differentiation in an infant. A bedside calculation
of ALC < 2500/mm3 in the neonatal period or infancy
should alert the physician towards the possible
diagnosis of SCID and further evaluation should be
done. Confirmatory tests include flow cytometry,
which shows very low B and T cell subsets, low
immunoglobulin levels, and mitogen stimulation assay
that detect abnormal or dysfunctional lymphocytes.7
There is a complete dearth of knowledge regarding the
incidence of SCID in Pakistan. With the high rate of
consanguineous marriages, the incidence is likely to
be high. However, if children with SCID are to be
successfully treated with early stem cell transplant, the
health care community needs to be sensitized about the
prevalence and early diagnosis of this disorder. 
The aim of this study was to describe the clinical
characteristics and laboratory features of SCID in infants
admitted at the study centre.
METHODOLOGY
This is a case series of infants with discharge diagnosis
of SCID at the Aga Khan University Hospital (AKUH),
Karachi, during five years (June 2006 till July 2011).
Patients were identified by health information
management system using coded discharge diagnosis
of combined immunity deficiency (ICD9 CM 279.2). This
coding contains SCID.
Features including the age on admission, gender,
anthropometry, past admissions, family history of early
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deaths and miscarriages, patient microbiological and
immunological profile (ALC, cluster of differentiation
(CD) markers count; serum immunoglobulin levels; HIV)
and duration of hospitalization were recorded. The ALC
was calculated from the first available complete blood
count that could have been done prior to, or at the time
of hospitalization. 
Cases were diagnosed on the basis of clinical presen-
tations and laboratory investigations; ALC < 2500/mm3,
low serum immunoglobulin levels (according to age) and
extremely low B and T cell subsets {suggestive clinical
presentation - recurrent diarrhea, pneumonia and
pyogenic infections; failure to thrive (FTT), family history
of sibling death due to recurrent infections, oral thrush
and absence of lymphoid tissue}.1,8
Descriptive statistics has been used for computing
frequency and percentage. The Ethical Review
Committee of the AKU granted an exemption for this
study (1950-Ped-ERC-11).
RESULTS
Among the 13 SCID infants, the mean age was 143 ± 70
days (median 154 days). Males (n = 10, 77%) were
predominant. Eleven (85%) were severely malnourished
(weight/age < 3 SD). Fever (n = 7; 54%), respiratory
distress (n = 7; 54%), persistent cough (n = 5; 38%),
poor oral intake (n = 4; 31%) and loose stools (n = 4;
31%) were the presenting complaints. Parents of nine
infants had consanguineous marriage. More than half
(n = 7, 54%) of the patients had family history of infant
deaths of undiagnosed cause while 3 (23%) had family
history of recurrent miscarriages. The ALC ranged
between 170 – 2280/mm3 (Table I). CD counts and
serum immunoglobulin levels were not available for 3
patients. The diagnosis of these patients was made on
their clinical presentation (recurrent infections and
failure to thrive), as well as supportive lab investigations
including low ALC, low lymphocyte subsets and
immunoglobulin levels. HIV status was checked for 5
patients and found to be negative. Mean length of
hospitalization was 10.9 ± 10 days. Three children had
positive bacterial cultures. Table II shows the spectrum
of microorganisms isolated from blood, urinary,
respiratory and from the stool of the patients.
DISCUSSION
SCID is a genetic disease with severe abnormalities of
immune function and development. Infants with SCID
usually appear normal and healthy at birth but within
1 – 2 months, the transplacentally acquired immunity
(immunoglobulin) starts waning, and infants develop
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Table I: Demographic and immunological profile of SCID patients.
Patient Age at Gender     Anthropometry CD4/CD8 Absolute CD3 CD4 CD8 CD19 CD 56 IgG IgM IgA HIV 
presen- ratio lymphocyte (2800- (1700- (800- (1000- (300- status
tation Wt. Lgt. FOC count 3500) 3500) 1100) 1700) 800) checked
(days) (ALC)*
1 177 F ∆ - - Reversed 393 - - - - - 0.07 0.36 0.11 No
2 49 M - - - Maintained 747 - - - undetectable - 0.07 6.26 0.94 No
3 82 M - - - -- 297 Severely Severely Severely undetectable Relatively 0.23 3.07 0.13 Yes
decreased decreased decreased increased
4 195 M ∆ - - Reversed 2100 Severely Severely Severely Mildly low - 0.66 0.07 0.33 Yes
decreased decreased decreased
5 184 M ∆ - - -- 413 31 - - 2 - - - - No
6 90 M ∆ ∆ ∆ Reversed 282 Severely 290 543 undetectable 15 - - - No
decreased
7 90 F ∆ - ∆ -- 1400 - - - - - 0.07 1.91 0.23 Yes
8 150 M ∆ - - Maintained 393 - - - - - 0.6 0.1 94 No
9 240 M ∆ - - Maintained 340 180 203 144 1 46 0.07 0.44 0.06 Yes
10 37 M ∆ ∆ ∆ Maintained 170 195 41 18 13 28 3.51 0.11 0.13 No
11 120 M ∆ - - Maintained 2280 430 255 196 143 4 - - - No
12 150 M ∆ - - Reversed 1270 37 31 27 9 800 - - - No
13 268 F ∆ - - Reversed 478 31 23 30 364 9 - - - Yes
M = male;   F = female;   CD = Cluster of differentiation;   *ALC = calculated from the first ever complete blood count;   Wt. = weight;   Lgt. = length;   FOC = Fronto-occipital circumference;
∆ = < 3 SD - severely malnourished.
Table II: Microorganisms isolated in SCIDS patients.
Patient Blood isolates Urinary isolates Respiratory isolates Stool isolates
3 – Candida albicans – Campylobacter jejuni
Escherichia coli
Aeromonas species
7 – – – Campylobacter jejuni
9 Staphylococcus epidermis – – –
10 Acinetobacter species – Escherichia coli –
11 Acinetobacter species Candida tropicalis Klebseilla pneumoniae Candida tropicalis –
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severe and recurrent life threatening infections.9,10
The median age of diagnosis worldwide is reported to be
4 – 7 months of age.4,11 Median age of diagnosis in this
cohort was 5 months.
Male infants were predominant in this cohort. The slight
male predominance has been reported previously in the
literature with M:F ratio varying from 1.5 – 2:1 (12, 13).
X-linked SCID is the most common form and accounts
for approximately 46%.7 One possible explanation of the
high male predominance in this cohort could be X-linked
SCID. The X-linked affected patients have no T cells or
NK cells in the peripheral blood, but have normal
number of B cells. Their immunoglobulin levels are low
or undetectable with absent lymph nodes and tonsils.8,10
Among the 10 male patients in this cohort, parents of
eight had consanguineous marriages and had very low
ALC; undetectable to very low NK cells and markedly
low serum immunoglobulin levels. While not formally
tested, it is probable that many of these had X-linked
variation of SCID.
FTT is one the common clinical presentation of infants
with SCID. Recurrent gastrointestinal and respiratory
infections are the basic reason of FTT in SCID patients.
Shah has found 100% FTT in their SCID patients case
series from India.9 Majority of the present study subjects
were severely malnourished.
Consanguinity increases the risk of rare inherited
disorders.5,14 Subbarayan et al. retrospectively reviewed
the clinical features of children diagnosed as primary
immunodeficiency at their immunology centres
(Manchester and New Castle) and found that 33%
(111/334) of children with B and T cell immunodeficiency
were Pakistani in origin.1 This was a significant over-
representation compared to the proportion of Pakistani-
origin children in their catchment area.
SCID is a medical emergency. The best screening test
for SCID is to check the ALC in all neonates and infants.
However, this represents a challenge in a country where
the majority of births take place at home and newborns
are not seen by physicians. In this environment, perhaps
a strategy of screening young infants from families
having early sibling death may pick-up a substantial
SCID cases. The ALC of < 2500/dL should alert the
physician towards the possibility of SCID and child
should be referred for confirmation (flow cytometry and
immunoglobulin level).
The good feature of HSCT therapy for SCID is its easy
acceptance in the recipient. Pre-requisites for SCID
transplantation require only human leukocyte antigen
matching (related or unrelated donor).15 The biggest
challenge is the unavailability of transplant centres
and cost of transplantation in developing countries
like Pakistan. None of these patients could receive
transplantation due to late presentation, lack of trans-
plant set up in neonates at that time, and financial
constraints of parents.
To the best of authors' knowledge, this is the first study
of any kind about SCID in Pakistan. This study had a few
limitations. This is a retrospective chart review of
inpatients only and not the outpatients, therefore, the
true burden of SCID seen in the hospital is likely to be
more than the report based on this inpatient case series.
The true confirmatory tests, including molecular testing
and mitogen stimulation assay could not be done
because of lack of facilities. However, using the current
criteria of severe lymphopenia and extremely low B and
T cell subsets, the likelihood that our diagnosis was
correct is very high.
CONCLUSION
SCID is an important cause of early infant deaths in a
country with one of the highest rates of consanguinity.
Increased awareness and educating health care
providers regarding SCID may lead to earlier diagnosis
and potential therapy. Systemic studies documenting the
contribution of serious inherited disorders to infant
mortality in Pakistan are also needed.
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